We are a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 250 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and China.

These products include a novel oral therapy for inflammatory bowel disease which is Phase III in the US & Europe; a novel oral selective c-Met inhibitor in phase II in Australia, China & the United States; four differentiated oral NCEs in oncology in Phase I & Phase II in China; and one oral NCE for inflammation in Phase I in Australia. Multiple NCEs are also in preclinical development.

After founding the company in 2002, we have built one of the largest and most experienced new drug R&D teams in China. We are led by a strong senior management team, all of whom have many years of experience succeeding at large US pharmaceutical and biotech companies. Our strategic partnerships have involved global, innovative companies such as AstraZeneca, Johnson & Johnson, Eli Lilly, Merck Serono and Nestlé Health Science in both oncology and inflammation.

和記黃埔醫(yī)藥（上海）有限公司（以下稱(chēng)“和記黃埔醫(yī)藥”）是中國(guó)最為領(lǐng)先的新藥研發(fā)企業(yè)之一。公司致力于研發(fā)具有自主知識(shí)產(chǎn)權(quán)保護(hù)的治療癌癥和自身免疫性疾病的創(chuàng)新藥物。目前公司共有研發(fā)人員250余名。

和記黃埔醫(yī)藥的在研新藥包括：在美國(guó)和歐洲進(jìn)入臨床三期試驗(yàn)的用于治療潰瘍性結(jié)腸炎的新型口服藥物；在澳大利亞、中國(guó)和美國(guó)進(jìn)行臨床二期試驗(yàn)的新型抗癌藥物c-Met口服抑制劑；在中國(guó)進(jìn)行臨床一期和二期試驗(yàn)的四個(gè)小分子口服腫瘤抑制劑；在澳大利亞進(jìn)行臨床一期試驗(yàn)的炎癥領(lǐng)域新型口服小分子藥物以及多個(gè)處于臨床前研究階段的小分子藥物。

和記黃埔醫(yī)藥成立于2002年，經(jīng)過(guò)多年發(fā)展，逐漸發(fā)展成為中國(guó)最大、最有經(jīng)驗(yàn)的新藥研發(fā)企業(yè)之一。公司擁有一流的創(chuàng)新藥物研發(fā)管理團(tuán)隊(duì)，管理團(tuán)隊(duì)成員皆有在美國(guó)大型制藥公司或生物公司的管理經(jīng)驗(yàn)。近幾年來(lái)，和記黃埔醫(yī)藥與全球知名醫(yī)藥研發(fā)機(jī)構(gòu)如雀巢、阿斯利康、美國(guó)強(qiáng)生、美國(guó)禮來(lái)等建立了戰(zhàn)略合作伙伴關(guān)系，共同研發(fā)造福于全球病患的創(chuàng)新藥物。

www.hmplglobal.com
www.Chi-med.com